The OECD Competition Committee held a roundtable discussion on Generic Pharmaceuticals in October 2009. This document includes an executive summary and the documents from the meeting: an analytical note by the staff of the United States Federal Trade Commission, written submissions from Canada, the Czech Republic, the European Commission, India, Indonesia, Ireland, Italy, Japan, Korea, Norway, the Russian Federation, South Africa, Spain, Sweden, the United Kingdom, the United States, and BIAC, as well as an aide-memoire.
Generic Pharmaceuticals
Key findings, summary and notes
Policy paper
Share
Facebook
Twitter
LinkedIn
Abstract
In the same series
-
1 June 202650 Pages -
14 November 202570 Pages
-
14 November 202560 Pages
-
14 November 202554 Pages
Related publications
-
1 June 202650 Pages -
18 May 2026267 Pages -
18 March 202655 Pages